Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors

This study has been completed.
Sponsor:
Collaborators:
Blood Center of Wisconsin
Key Biologics, LLC
LeukoLab
Yale University
Information provided by (Responsible Party):
Terumo BCT
ClinicalTrials.gov Identifier:
NCT01277549
First received: January 13, 2011
Last updated: May 2, 2013
Last verified: May 2013
  Purpose

The purpose of this protocol is to characterize the performance of CaridianBCT's Spectra Optia Apheresis System, when used to collect mononuclear cells (MNCs) and cluster of differentiation 34 (CD34) positive cells from healthy nonmobilized blood donors and healthy G-CSF (granulocyte colony stimulating factor) mobilized blood donors, respectively.


Condition Intervention
Leukapheresis
Device: Mononuclear cell collection.

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors

Resource links provided by NLM:


Further study details as provided by Terumo BCT:

Primary Outcome Measures:
  • Mononuclear Cell Collection Efficiency [ Time Frame: One day ] [ Designated as safety issue: No ]
    The collection efficiency for a given cell type is defined as the percent of processed cells of that cell type that are in fact collected.

  • CD34+ Cell Collection Efficiency [ Time Frame: one day ] [ Designated as safety issue: No ]
    The collection efficiency for CD34+ cells is defined as the percent of processed CD34+ cells that were in fact collected.


Secondary Outcome Measures:
  • Platelet Collection Efficiency [ Time Frame: One Day ] [ Designated as safety issue: No ]
    Platelet contamination of the cell product was measured as the platelet collection efficiency, that is, as the percent of platelets processed that were collected.

  • Hematocrit of MNC Product [ Time Frame: One Day ] [ Designated as safety issue: No ]
    The hematocrit of the collected product was used to quantitate RBC (red blood cell) contamination.

  • Granulocyte % of MNC Product [ Time Frame: One day ] [ Designated as safety issue: No ]
    Granulocyte contamination of the MNC product was quantitated as the percent of total product WBC (white blood cell) that were segmented granulocytes or bands.

  • Viability of the Collected MNC Product [ Time Frame: One day ] [ Designated as safety issue: No ]
    The viability of the collected white blood cells was assessed using the 7-AAD (7-amino actinomycin D) viability dye in a flow cytometric assay. Viability assessment is incorporated into the CD34 assay. This assay was only performed on G-CSF mobilized donors as nonmobilized donor have too few CD34+ cells to detect. Thus viability of the collected WBCs is reported only for the G-CSF mobilized arm.


Enrollment: 71
Study Start Date: January 2011
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Non-mobilized donors
In this arm the collection efficiency of mononuclear cells from non-mobilized donors will be studied.
Device: Mononuclear cell collection.
Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
G-CSF mobilized donors
In this arm the collection efficiency of CD34+ cells will be studied.
Device: Mononuclear cell collection.
Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy Community Volunteers

Criteria

Inclusion Criteria:

  • Acceptable health history to allow blood product collection
  • Weight >50<125 Kg (kilogram).
  • Male or non-pregnant, non-nursing female.
  • General good health, as determined by questionnaire.
  • Normal prescreening complete blood count.
  • Platelet count>150 x 10^3/uL (microliter) at initial screening and >120 x 10^3/uL immediately prior to leukapheresis.
  • Adequate peripheral venous access to allow collection of product.
  • Able to read, understand, and sign the informed consent form. Additional Inclusion Criteria for Mobilized Subjects
  • If male, be willing to use a condom during sexual relations with a female partner until 48 hours following the last G-CSF injection.
  • If female and of childbearing potential, be willing to use a medically acceptable contraceptive until 48 hours following the last G-CSF injection.

Exclusion Criteria:

  • a) Collection or loss of:

    • more than a ½ pint (1 cup) of whole blood within the prior 56 days or,
    • more than 3 L (liter) of whole blood or 1.5 L of red blood cells within the prior 12 months or,
    • more than 12 L of plasma within the prior 12 months or,
    • a leukapheresis within the prior six weeks or,
    • a plateletpheresis within the prior 48 hours or two within the prior 7 days or twenty-four within the last 12 months or,
    • a plasmapheresis within the prior 48 hours or two within the prior 7 days.
  • Acute or symptomatic chronic lung disease.
  • Active or chronic heart disease, including hypertension controlled by medication.
  • History of hematologic malignancy or chronic hematologic disorder or bleeding disorder.
  • Reactive test indicative of infection with T. pallidum, Human T-lymphotropic virus, HIV, Hepatitis C Virus, or Hepatitis B Virus (except isolated Hepatitis B Core Antibody Reactivity.
  • Presence of psychological traits or physiological or medical conditions that would make subject unlikely to tolerate the procedures.
  • Subjects taking prescription medications other than those deemed allowable by the investigator.
  • Abnormal serum electrolytes or serum calcium levels.
  • Abnormal serum creatinine level.
  • Abnormal liver function results on ALT (alanine amino transferase) test.
  • Abnormal coagulation testing on prothrombin time or partial thromboplastin time.
  • Inadequate antecubital veins for leukapheresis or inability or unwillingness to tolerate leukapheresis.
  • If female, pregnant or lactating. Additional Exclusion Criteria for Mobilized Subjects
  • Received a G-CSF injection in the prior 4 months, or received more than twenty-five (25) doses of G-CSF (a dose includes several individual injections administered on one occasion).
  • Known hypersensitivity to G-CSF or any E. coli-derived products.
  • History of autoimmune condition or disorder, unless approved by principal investigator.
  • Immediate family history (parents, grandparents, siblings, children) of hematologic malignancy.
  • Active or history of iritis (anterior uveitis) or episcleritis.
  • History of deep vein thrombosis or pulmonary embolism.
  • Current treatment with lithium.
  • Spleen tip palpable during physical exam.
  • Positive SickleDex test.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01277549

Locations
United States, California
Leukolab/Allcells
Emeryville, California, United States, 94608
United States, Tennessee
Key Biologics
Memphis, Tennessee, United States, 38104-3401
United States, Wisconsin
Blood Center of Wisconsin
Milwaukee, Wisconsin, United States, 53233
Sponsors and Collaborators
Terumo BCT
Blood Center of Wisconsin
Key Biologics, LLC
LeukoLab
Yale University
Investigators
Study Director: Jerome R Bill, MD Terumo BCT
  More Information

No publications provided

Responsible Party: Terumo BCT
ClinicalTrials.gov Identifier: NCT01277549     History of Changes
Other Study ID Numbers: BCT10-03
Study First Received: January 13, 2011
Results First Received: September 11, 2012
Last Updated: May 2, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Terumo BCT:
Leukapheresis
Hematopoetic Stem Cell Mobilization

ClinicalTrials.gov processed this record on October 16, 2014